Search

Displaying results 661 - 670 of 4207 in total
  1. Drug

    Primaquine

    go.drugbank.com/drugs/DB01087
    ApprovedInvestigational

    An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. … It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.

  2. Drug

    Benzydamine

    go.drugbank.com/drugs/DB09084
    ApprovedInvestigational

    benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but

  3. Drug

    Prochlorperazine

    go.drugbank.com/drugs/DB00433
    ApprovedInvestigationalVet approved

    [L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. … [label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.

  4. Drug

    Vancomycin

    go.drugbank.com/drugs/DB00512
    ApprovedInvestigational

    29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of _Clostridium difficile_ associated diarrhea and enterocolitis caused by

  5. Drug

    Donidalorsen

    go.drugbank.com/drugs/DB18751
    ApprovedInvestigational

    Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin. … [L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783]

  6. Drug

    Nifedipine

    go.drugbank.com/drugs/DB01115
    ApprovedInvestigational

    Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine]. … [A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.

  7. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents.

  8. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It was developed by The Medicines Company (acquired by Novartis). … Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629]

  9. Drug

    Doxorubicin

    go.drugbank.com/drugs/DB00997
    ApprovedInvestigational

    [A257614] Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin

  10. Drug

    Cyanocobalamin

    go.drugbank.com/drugs/DB00115
    ApprovedInvestigationalNutraceutical

    This drug was initially approved by the FDA in 1942 [FDA label]. … This vitamin is produced naturally by bacteria [A175276], and is necessary for DNA synthesis and cellular energy production.